uniQure N.V.
QURE · XNASCIK 1590560fmd_02N9NDKPB80N775S12EJ5Q68SFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 45 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 25 | 13 | 11 | 7 | 38 | 524 | 106 | 16 | 27 | 16 |
| Cost of revenue | 1 | 1 | 1 | 2 | 3 | 25 | 1 | 0 | 1 | 2 |
| Gross profit | 24 | 12 | 10 | 6 | 35 | 499 | 105 | 16 | 26 | 14 |
| Research and development | 73 | 72 | 75 | 95 | 122 | 144 | 198 | 215 | 144 | 141 |
| Selling, general and administrative | 26 | 25 | 25 | 34 | 43 | 56 | 55 | 75 | 53 | 65 |
| Compensation and benefits | 42 | 46 | 46 | 59 | 76 | 96 | 120 | 136 | – | – |
| Total operating expenses | 99 | 97 | 100 | – | – | – | – | – | – | – |
| Operating income | (72) | (71) | (88) | (121) | (125) | 311 | (143) | (283) | (184) | (185) |
| Interest expense | 2 | 2 | 2 | 4 | 4 | 7 | 12 | 42 | 64 | 62 |
| Interest and investment income | 0 | 0 | 3 | 4 | 1 | 0 | 1 | 20 | 21 | 17 |
| Other non-operating income (expense) | 1 | (2) | 0 | (3) | 0 | (0) | 3 | – | – | 11 |
| Income before taxes | (72) | (79) | (83) | (124) | (141) | 333 | (128) | (307) | (237) | (193) |
| Income tax expense | 1 | (0) | 0 | – | (16) | 3 | (1) | 2 | 2 | 6 |
| Net income from continuing operations | (73) | (79) | (83) | – | (125) | 330 | (127) | (308) | (240) | (199) |
| Net income | (73) | (79) | (83) | (124) | (125) | 330 | (127) | (308) | (240) | (199) |
| Net income to common shareholders | (73) | (79) | (83) | (124) | (125) | 330 | (127) | (308) | (240) | (199) |